Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MRTX0902 |
| Synonyms | |
| Therapy Description |
MRTX0902 inhibits SOS1, blocking interaction with Kras and potentially reducing tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr ND02). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MRTX0902 | MRTX-0902|MRTX 0902 | SOS1 Inhibitor 17 | MRTX0902 inhibits SOS1, blocking interaction with Kras and potentially reducing tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr ND02). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05578092 | Phase Ib/II | Adagrasib + MRTX0902 MRTX0902 | A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | Active, not recruiting | USA | 1 |